Authors show the PREVENT algorithm from the American Heart Association does not adequately predict #cardiovasculardisease risk in a large multicentre cohort of PWH in the USA & may lead to failure to prescribe statins to PWH unless guidelines change. 🔗 https://t.co/OBa3cbAcji

Heart failure is a major contributor to the global burden of cardiovascular disease. It affects more than 55 million people 🫀 A new Lancet Series calls for a reframe—heart failure as preventable chronic disease. Read this, a linked Editorial, & more 👉 https://t.co/fjhB21cpOM

📢 Largest study to date of HFimpEF—out in JACC! 🫀 Among >28K new HFrEF patients, 1 in 3 improved to HFimpEF within 12 months ⚠️ Risk remains: • HF events ↓ • Mortality ↓ • GDMT use declined 🔍 Continuing GDMT is critical. @ankeetbhatt @ATSandhu https://t.co/1l742eArY3

For people with #HIV, new @AHAScience PREVENT equations predict lower 10 year heart risk than the PCE so fewer will be prescribed statins if widely adopted w/o changing guidelines: validation is needed in this high-risk group! @durstenfeld Read in #JGIM: https://t.co/Yu5G8kfnei

New pub @JournalGIM : for people w #HIV new @AHAScience PREVENT equations predict ⬇️risk of 🫀events than older pooled cohort equations (which underestimate risk), would result in fewer statin prescriptions if adopted. Urgently need calibration study 4 PWH

UCSF scientists had a hypothesis: What if lingering bits of the coronavirus were causing debilitating long COVID symptoms?  https://t.co/8edd7IpWQF

https://t.co/5goAcQApWD via @NYTimes

Contribute to the Long COVID and Post-Acute Infection Syndromes discussion! Submit abstracts and scholarships by May 13, 11:59 PM MST. Hear @MichaelPelusoMD and top experts in infectious disease and immunology. Act now: https://t.co/ogwaGyrLP2! #KSLongCOVID26 #LongCOVID

This is terrible: NIH to end billions of dollars in foreign research grants

To counter pill-burden, a major barrier to HF GDMT adherence, polypills are being investigated. In this #ACCSimPub the authors developed polypill prototypes & manufacturing pathways w/pharmacy partners. Clinical trials are underway to study this strategy.🔗 https://t.co/U0lYwQWnkL

"no one has died" because of feeding USAID to the woodchipper, Elon claimed. In this devastating piece the NYT went out and learned some of their names and stories:

❗️New paper: does a cardiologist clinic visit prevent cardiovascular events for people w #HIV without known 🫀disease? see what our team found in the @NIMHD funded PATHWAYS study here: https://t.co/GFJGKFzKqz @hivcardiodoc @DCRINews @UCSFCardiology

Yes, the US government has been subsidizing science. That is not a weakness of our system. It is one of our greatest strengths. Turning our back on NIH and the institutions who do science for the sake of science, not profit, debases us all.

NIH just made a drastic change to indirect cost rates, reducing the rate to 15%, a significant cut from the 60%+ some institutions charge. This will have a devastating effect on the nation’s medical research infrastructure. @ResearchAmerica @AAMC @YaleMed

James N. Kirkpatrick, MD, FACC, a leader in echocardiography, a gifted mentor and teacher, and a pioneer in the field of medical ethics, passed away unexpectedly on Jan. 1. Read more about his life and contributions to cardiology with reflections from ACC leaders:

It is with immense sadness that we announce a dedicated ASE and #ASEFoundation champion, James Kirkpatrick, passed away yesterday. He was a highly respected colleague & mentor. His devotion to his patients & the #EchoFirst field will be greatly missed. https://t.co/YWVLHZPVYp

❗️New Paper: HIV‐Associated Heart Failure: Phenotypes and Clinical Outcomes in a Safety‐Net Setting: #HIV associated w⬆️risk of 🪦 among people with #HF 🫀 https://t.co/bUweXEuETR @JAHA_AHA @AHAScience @UCSFCardiology @ZSFGCare

Key stakeholders perceive a HFrEF polypill to be a highly acceptable, feasible, and appropriate strategy to improve care of HFrEF patients @WashUCardiology @WUDeptMedicine @durstenfeld @colettedejong #AHAJournals https://t.co/J2gE944CBR

Our mechanistic review of #LongCovid - published in @CellCellPress - hopefully will be helpful coming out of the very inspiring RECOVER-Treating Long COVID meeting this week. Excited for the progress we will make together in the next year! https://t.co/JUYQnXYRlO

This paper on thromboinflammation is everywhere this week. Unfortunately nobody commenting on it seems to have read it! I have, and it definitely doesn't say what commentators are suggesting. 🧵 https://t.co/howINhQUOE